[HTML][HTML] Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network
Z Vinarov, B Abrahamsson, P Artursson… - Advanced Drug Delivery …, 2021 - Elsevier
Although oral drug delivery is the preferred administration route and has been used for
centuries, modern drug discovery and development pipelines challenge conventional …
centuries, modern drug discovery and development pipelines challenge conventional …
Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology
MAC Bruin, GS Sonke, JH Beijnen… - Clinical …, 2022 - Springer
Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP)
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …
inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer …
A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system
Y Shu, X He, Y Liu, P Wu, Q Zhang - Clinical epidemiology, 2022 - Taylor & Francis
Background Olaparib, the world's first poly ADP-ribose polymerase (PARP) inhibitor
(PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic …
(PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic …
Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future …
KS Taskar, V Pilla Reddy, H Burt… - Clinical …, 2020 - Wiley Online Library
Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to
quantitatively translate in vitro data and evaluate temporal effects from drug–drug …
quantitatively translate in vitro data and evaluate temporal effects from drug–drug …
A review of CYP3A drug-drug interaction studies: Practical guidelines for patients using targeted oral anticancer drugs
L Molenaar-Kuijsten, DEM Van Balen… - Frontiers in …, 2021 - frontiersin.org
Many oral anticancer drugs are metabolized by CYP3A. Clinical drug-drug interaction (DDI)
studies often only examine the effect of strong CYP3A inhibitors and inducers. The effect of …
studies often only examine the effect of strong CYP3A inhibitors and inducers. The effect of …
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific …
N Djebli, N Parrott, F Jaminion… - CPT …, 2024 - Wiley Online Library
Glofitamab is a novel T cell bispecific antibody developed for treatment of relapsed‐
refractory diffuse large B cell lymphoma and other non‐Hodgkin's lymphoma indications. By …
refractory diffuse large B cell lymphoma and other non‐Hodgkin's lymphoma indications. By …
PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer
R Ambur Sankaranarayanan, A Florea, S Allekotte… - EJNMMI research, 2022 - Springer
Background Triple-negative breast cancer (TNBC) lacks biomarkers for targeted therapy.
Auger emitters display the best therapeutic effect, if delivered directly into the nucleus …
Auger emitters display the best therapeutic effect, if delivered directly into the nucleus …
Association between olaparib exposure and early toxicity in BRCA-mutated ovarian cancer patients: results from a retrospective multicenter study
M Velev, A Puszkiel, B Blanchet, S de Percin… - Pharmaceuticals, 2021 - mdpi.com
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The
large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of …
large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of …
Ovarian cancer in the older patient: where are we now? What to do next?
F Rousseau, F Ranchon, C Bardin… - Therapeutic …, 2023 - journals.sagepub.com
In recent years, major advances have been made toward the individualization of epithelial
ovarian cancer care, leading to an overall improvement of patient outcomes. However, real …
ovarian cancer care, leading to an overall improvement of patient outcomes. However, real …
Pharmacokinetics under the COVID‐19 storm
V Pilla Reddy, E El‐Khateeb, H Jo… - British journal of …, 2023 - Wiley Online Library
Aims The storm‐like nature of the health crises caused by COVID‐19 has led to
unconventional clinical trial practices such as the relaxation of exclusion criteria. The …
unconventional clinical trial practices such as the relaxation of exclusion criteria. The …